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Background: Diabetes mellitus (DM) and thyroid dysfunction (TD) are the two most common endocrine disorders
in clinical practice. The unrecognized TD may adversely affect the metabolic control and add more risk to an
already predisposing scenario for cardiovascular diseases. The objective of this study was to investigate the
prevalence of TD in patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM).
Methods: This is an observational cross-sectional study. Three hundred eighty-six (386) patients with T1DM or
T2DM that regularly attended the outpatient clinic of the Diabetes unit, Hospital Universitário Pedro Ernesto,
participated in the study. All patients underwent a clinical and laboratory evaluation. Thyroid dysfunction was
classified as clinical hypothyroidism (C-Hypo) if TSH > 4.20 μUI/mL and FT4 < 0.93 ng/dL; Subclinical
hypothyroidism (SC-Hypo) if TSH > 4.20 μUI/ml and FT4 ranged from 0.93 to 1.7 ng/dL; Subclinical hyperthyroidism
(SC-Hyper) if TSH < 0.27 μUI/ml and FT4 in the normal range (0.93 and 1.7 ng/dL) and Clinical hyperthyroidism
(C-Hyper) if TSH < 0.27 μUI/ml and FT4 > 1.7 μUI/mL. Autoimmunity were diagnosed when anti-TPO levels were
greater than 34 IU/mL. The positive autoimmunity was not considered as a criterion of thyroid dysfunction.
Results: The prevalence of TD in all diabetic patients was 14,7%. In patients who had not or denied prior TD the
frequency of TD was 13%. The most frequently TD was subclinical hypothyroidism, in 13% of patients with T1DM
and in 12% of patients with T2DM. The prevalence of anti-TPO antibodies was 10.8%. Forty-four (11.2%) new cases
of TD were diagnosed during the clinical evaluation. The forty-nine patients with prior TD, 50% with T1DM and
76% with T2DM were with normal TSH levels.
Conclusions: We conclude that screening for thyroid disease among patients with diabetes mellitus should be
routinely performed considering the prevalence of new cases diagnosed and the possible aggravation the
classical risk factors such as hypertension and dyslipidemia, arising from an undiagnosed thyroid dysfunction.
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Diabetes Mellitus (DM) and thyroid dysfunction (TD) are
the two most common endocrine disorders in clinical
practice [1]. The association between DM and TD is
widely known, with the first studies published in 1979 [2].
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reproduction in any medium, provided the orconducted to estimate the prevalence of TD in diabetic
patients. There is great variability in the prevalence of TD
in general population, ranging from 6.6% to 13.4% [3,4]. In
diabetic patients, the prevalence is still greater and varies
from 10 to 24% [4,5]. These differences can be explained
by different diagnostic criteria of TD, the degree of iodine
intake among different regions, different sensitivities of
the TSH assays and the large population diversity [6]. The
relationship between TD and DM is characterized by a
complex interaction of interdependence. Screening of TD,
especially the subclinical dysfunction, in patients with DMtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Determine the prevalence of clinical and subclinical
thyroid disease in diabetic patients in our country and
its implications in the course of diabetes and known
factors for cardiovascular risk is necessary. The aim of
this study is to investigate the prevalence of TD in pa-
tients with type 1 (T1DM) and type 2 diabetes mellitus
(T2DM) in clinical routine.
Methods
This is an observational cross-sectional study. Three
hundred eighty-six (386) patients with T1DM or T2DM
that regularly attended the out-patient clinic of the unit of
Diabetes, at Hospital Universitário Pedro Ernesto partici-
pated in the study. The inclusion criteria was duration of
DM longer than 6 months for patients with T2DM
or 1 year for those with T1DM. Patients were diag-
nosed to have type 2 DM when it was diagnosed with an
age ≥30 years, without insulin use in the first year after
diagnosis and without history of ketosis or ketonuria. In
T1DM patients, the diagnosis was based on typical clinical
presentation, a variable degree of weight loss, polyuria,
polydpsia and polyphagia and the need to use insulin con-
tinuously since the diagnosis without discontinuation and
medical follow-up for at least 1 year. Written informed
consent for the study was obtained from all of the patients
aged 18 years or older or from the parents or guardians of
the patients younger than 18 years. Patients or guardians
who were unable to understand and sign the informed
consent, pregnant women, patients with recent inter-
ventions: pulse corticosteroids and/or radioiodine, use
of amiodarone and with a history of hospitalization for
less than 6 months were excluded.
The study protocol was approved by the research
ethics committee of Hospital Universitário Pedro Ernesto
(HUPE).
All patients underwent a clinical and laboratory evalu-
ation. The demographic data were obtained from a survey.
The following variables were assessed: gender, age (years),
ethnicity (Caucasian/non-caucasian), duration of DM
(years), BMI, blood pressure (systolic and diastolic). Data
on comorbidities such as hypertension, dyslipidemia, previ-
ous TD (hyperthyroidism, hypothyroidism, nodules, can-
cer), were also taken. Blood samples were obtained after a
12 hour overnight fast for biochemical analysis: fasting and
2 h-postprandial glycemia, HbA1c, anti-thyroperoxidase
antibody (anti-TPO), free thyroxine (FT4) and thyrotropin
(TSH). The reference values and intra-assay and inter-assay
coefficients of variation were, respectively, <34 IU/mL, 3.4
and 7.6 for anti-TPO; 0.93 to 1.7 ng/dL, 1.8 and 3.0 for
FT4; 0.27 to 4.20 μUI/ml, 1.9 and 2.2 for TSH.
Thyroid dysfunction was classified as clinical hypothy-
roidism (C-Hypo) if TSH levels were greater than 4.20 μUI/
mL and FT4 levels were lower than 0.93 ng/dL; subclinicalhypothyroidism (SC-Hypo) if TSH levels were greater
than 4.20 μUI/ml and FT4 levels ranged from 0.93 μUI
to 1.7 ng/dL, subclinical hyperthyroidism (SC-Hyper) if
TSH levels were lower than 0.27 μUI/ml and FT4 levels
ranged from 0.93 and 1.7 ng/dL and clinical hyperthy-
roidism (C-Hyper) if TSH levels were lower 0.27 μUI/ml
and FT4 levels were higher than 1.7 ng / dL. Autoimmunity
were diagnosed when anti-TPO levels were greater than
34 IU/mL. The positive autoimmunity was not considered
as a criterion of thyroid dysfunction.
The sample size was calculated to estimate a prevalence
of 10%. About 300 patients with T2DM and 80 patients
with T1DM allowed to estimate the expected prevalences
by means of 95% confidence interval with an absolute pre-
cision of ± 3.5% and ± 4,5%, respectively. Statistical analysis
was performed using SPSS (Statistical Package for the
Social Sciences) for Windows (version 15.0). Categorical
variables were described as frequency (percentage), mean ±
standard deviation were used for continuous parameters.
Differences between two groups were compared by the
Student T test. For non-parametric variables, the data
are presented as median (min-max). In this case, the
nonparametric Mann–Whitney test was used for statis-
tical comparisons. Categorical variables were compared
between two or more groups using the Chi-square test.
For all analyses, a two-tailed p-value of <0.05 was con-
sidered statistically significant.Results
Overall 386 patients, 82 (21.2%) with T1DM and 304
(78.8%) with T2DM, were included. Clinical and demo-
graphic data of the studied population are presented in
Table 1.
The prevalence of TD in all diabetic patients was 14,7%.
Autoimmunity, considered as anti-TPO positive, were
present in 12 (14,6%) patients with T1DM and in 30
(9,9%) in T2DM patients.
The prevalence of SC-Hypo was 13% in T1DM patients
without previous TD and was the only TD found in
this group. In the group of patients with T2DM with-
out previous TD, the prevalence of SC-Hypo was 12%,
C- Hypo 0,7%, SC- Hyper 0,3% and C-Hyper 0,3%.
Data shown in Table 2.
Forty- four patients (13%) were diagnosed with TD
during the clinical evaluation. We diagnosed 9 (13%)
new cases of SC-Hypo in patients with T1DM and 31
(12%) new cases of SC-Hypo in patients with T2DM
who denied or ignored prior TD. SC-Hypo was the most
TD found in this diabetic group. Data presented in
Table 2. In patients who reported previous TD, 28 (76%)
of 37 T2DM patients and 6 (50%) of 12 T1DM patients
had TSH and FT4 levels in the normal range. Data
presented in Table 3.




Gender (female) n (%) 43 (52%) 204 (67%)
Age (years) 33.5 ± 15,8 60.7 ± 10.6
Diabetes duration (years) 14.6 ± 11.7 14.8 ± 10.5
Ethnicity, n (%)
Caucasian 37 (45%) 127 (42%)
Non-caucasion 45 (55%) 177 (58%)
Hypertension (yes) 16 (19.5%) 243 (79.9%)
Dyslipidemia (yes) 21 (25.6%) 209 (68.8%)
Previous thyroid disease n(%)
Yes 12 (15%) 37 (12%)
No 61 (74%) 184 (60%)
Unknown 9 (11%) 83 (28%)
BMI (kg/m2) 24,4 ± 5,2 30,3 ± 5,1
sBP (mmHg) 111 ± 16 131 ± 20
dBP (mmHg) 79 ± 10 75 ± 11
FPG (mg/dL) 141 ± 85,5 139 ± 74,9
2 h-PPG (mg/dL) 216 ± 96,0 215 ± 81,5
HbA1c (%) 12,3 ± 3,1 8,3 ± 1,8
TSH (μUI/mL) 2,60 ± 1,80 2,53 ± 2,24
FT4 (μUI/mL) 1,29 ± 0,17 1,31 ± 0,33
Anti-TPO (yes) 12 (14.6%) 30 (9.9%)
Data are presented as mean ± SD, n (%). sBP, systolic blood pressure; dBP,
diastolic blood pressure; BMI, body mass index; FPG, fasting blood glucose;
2 h- PPG, 2 h postprandial glucose.
Table 3 The frequencies of thyroid dysfunction of T1DM
and T2DM patients with prior TD
Thyroid function T2DM (n = 37) T1DM (n = 12)
Euthyroidism 28(76) 6(50)




SC-Hypo,subclinical hypothyroidism, C-Hypo,clinical hypothyroidism, SC-Hyper,
subclinical hyperthyroidism,C-Hyper, clinical hyperthyroidism. Data are
presented as n (%).
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This study demonstrated a 14,7% prevalence of TD in
the diabetic patients studied. Subclinical hypothyroidism
was the most frequent dysfunction found corresponding
to 11,8% of the patients which was similar to studies
already described in the literature [2,7] but higher than
that reported in studies with non-diabetics [8-10].
Analyzing data from T1DM patients, the frequency
of TD was 13% of SC -Hypo in patients without prior
TD and 14,6% anti-TPO positive. In the study byTable 2 The frequencies of thyroid dysfunction of T1DM
and T2DM patients without prior TD






SC-Hypo,subclinical hypothyroidism, C-Hypo,clinical hypothyroidism, SC-Hyper,
subclinical hyperthyroidism,C-Hyper, clinical hyperthyroidism. Data are
presented as n (%).Ramos et al. [11], where 126 patients with T1DM were
evaluated, the prevalence of TD was 20.6%. However,
they considered a positive test for autoimmunity as TD. In
the same study, the prevalence of SC-Hypo was 13.5% and
anti-TPO antibodies was 18.2%, but patients were younger
compared to our study. In the study by Souza et al. [12],
evaluating 101 patients with T1DM, the prevalence of
Sc-Hypo was 6.5% but FT4 was not used for diagnosis.
A prevalence of 30.7% of at least one antibody was
found positive in the same study, where 3 antibodies
were assayed: anti-thyroglobulin, anti-microssomal, and
anti-TPO. The variability of the laboratorial methods on
screening of thyroid autoimmunity could influence the
results described above because the latest studies use
anti-TPO as preferred test [12].
According to various studies, the prevalence of auto-
immunity in T1DM patients may vary between 3 and 50%
[13,14]. One factor that may account for this variability
could be the different laboratory methods used for the
evaluation of autoimmunity.
Nine new cases of DT were diagnosed in patients with
T1DM, whom ignored or denied prior TD. Patients
whom already known to have TD, only half (50%)
presented hormone levels in normal range. This data
are consistent with the NHANES study [10], where only
67% of individuals who self-reported having TD were
adequately treated. Non-adherence to therapy can be
explained by factors such as: the excess of medications
used due to comorbidities, adverse effects of medica-
tions, high cost, education of patients that limits access
to information, the asymptomatic nature of the disease
(in some cases) in which the importance of drug treatment
is not recognized [15]. Data from the study of “Adherence
to Medication for Chronic Diseases (diabetes and hyper-
tension) in the City of Teresina” demonstrated that the
degree of compliance percentage was lower than the
“recommended” [16] level of 80%. Other Brazilian stud-
ies demonstrated adherence rates of 11% in Bahia and
66.6% in São Paulo [17].
In the analysis of T2DM patients, we observed a
frequency of all TD of 13,1% and SC-Hypo of 12%. This
frequency found is higher than those described in the
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et cols. (8.4%) [19]. Previous studies have shown that
the risk of thyroid dysfunction increases with age
[11,15]. It is important to emphasize that our patients
with SC-Hypo are older than the two earlier studies afore
mentioned. These findings may be more favorable to
subclinical abnormalities that could explain the higher
frequencies found in our study. Subclinical TD are char-
acterized with biochemical changes without inclusion of
clinical signs or symptoms [20].
We observed a overall frequency of 10,8% positive
anti-TPO, 14,6% in T1DM and 9,9% in T2DM. The epi-
demiological study of Whickam [21], showed that 55%
of patients with elevated TSH and positive anti-thyroid
antibodies progressed to clinical hypothyroidism in con-
trast with 33% of those who had elevated TSH and
negative antibodies.
Some limitations of our study must be discussed. This
study was a cross- sectional with internal validity and we
used a convenience sample of diabetic patients already
treated in an university hospital. Some types of selection
bias may have occurred because these patients are
already under medical care. Some patients whom already
had prior knowledge of their thyroid function could have
some nonspecific symptoms of TD but not yet with
laboratorial confirmation. They might be more inter-
ested on research. However, all patients were submitted
to the same study protocol.
Other limitation of the study is that only one sample of
TSH and FT4 was collected, which may have contributed
to a high frequency of TD, since the phenomenon of re-
gression to the mean was not minimized by a second sam-
ple. However, the dosage of FT4 is not always included in
other prevalence studies like NHANES [10]. The level of
FT4 add a greater specificity in the detection of TD.
The strength of this study is the great number of pa-
tients (n = 386), more than described in other Brazilian
studies with diabetic patients mentioned previously
and the dosage of TSH, FT4 and anti-TPO using ultra-
sensitive laboratory tests performed in all patients.
This study joins previous studies to determine the
prevalence of thyroid dysfunction in diabetic patients
in Brazil and also includes a greater number of type 2
diabetic patients whose prevalence is poorly described
in previous studies.
Conclusion
In conclusion, the results of this cross-sectional study
showed a high prevalence of TD in the diabetic population
which indicates that screening for thyroid disease among
patients with diabetes should be routinely performed. The
prevalence of new cases of TD diagnosed and the possible
aggravation of classical risk factors such as hypertension
and dyslipidemia, arising from an undiagnosed thyroiddysfunction can lead to an increased cardiovascular risk in
these patients. However, we reinforce that prospective
studies and with more patients are necessary to clarify the
impact of thyroid disease in diabetic patients.
Abbreviations
C-Hypo: Clinical hypothyroidism; C-Hyper: Clinical hyperthyroidism;
DM: Diabetes mellitus; SC- Hypo: Subclinical hypothyroidism; SC-
Hyper: Subclinical hyperthyroidism; TD: Thyroid disfunction; T1DM: Type 1
diabetes mellitus; T2DM: Type 2 diabetes mellitus.
Competing interests
The authors declared that they have no competing interests related to this
manuscript.
Authors’ contributions
CCSSVP: has written the manuscript and collected data. MP: did the statistical
analysis. VGN, ELSC, MFBMPV, LCPJ, FFP, TGB, LFB, JOS, SCFS, VPLCC: have
collected data. MBG: has corrected the manuscript. All authors read and
approved this final manuscript.
Acknowledgments
This work was supported by grants from Fundação do Amparo à Pesquisa
do Estado do Rio de Janeiro- FAPERJ.
Author details
1Diabetes Unit, State University Hospital of Rio de Janeiro (UERJ), Avenida 28
de setembro, 77, Serviço de Diabetes, Terceiro andar, Vila Isabel, Rio de
Janeiro, Brazil. 2CLIF Data Centre, European Consortium on Liver Failure,
Hospital Clínic de Barcelona, Barcelona, Espanha.
Received: 29 July 2013 Accepted: 30 September 2013
Published: 9 October 2013
References
1. Hage M, Zantout MSM, Azar ST: Tyroid disorders and diabetes mellitus.
J Thyroid Res 2011, 2011:439463.
2. Papazafiropoulou A, Sotiropoulos A, Kokoloki A, Kardara M, Stamataki P,
e Pappas S: Prevalence of thyroid dysfunction among greek type 2
diabetic patients attending an outpatient clinic. J Clin Med Res 2010,
2:75–78.
3. Silva RC: Importância da avaliação da função tireodiana em pacientes
com diabetes mellitus. Arq Bras Endocrinol Metab 2005, 49(2):180–182.
4. Umpierrez GE, Latif KA, Murphy MB, Lambert HC, Stentz F, Bush A, et al:
Thyroid dysfunction in patients with type 1 diabetes. Diabetes Care 2003,
26:1181–1185.
5. Gharib H, Tuttle RM, Baskim J, Fish LH, Singer PA, McDermott MT:
Consensus statement. Subclinical thyroid dysfunction: a joint statement
on management from the American Association of Clinical
Endocrinologists, the American Thyroid Association and The Endocrine
Society. J Clin Endocrinol Metab 2005, 90:581–585.
6. Chen G, Juan W, Yinghua L, et al: Associations between cardiovascular
risk, insulin resistence, β- cell function and thyroid dysfunction : a cross-
sectionsl study in She ethnic minority group of Fujian Province in China.
Euro J Endocrinol 2010, 163:775–782.
7. Perros P, McCrimmon RJ, Shaw G, Frier BM: Frequency of thyroid
dysfunction in diabetic patients: value of annual screening. Diabet Med
1995, 12(7):622–627.
8. Tunbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al: The
spectrum of thyroid disease in a community: the whickham survey. Clin
Endocrinol (Oxf ) 1977, 7(6):481–493.
9. Canaris GJ, Manowitz NR, Mayor G, Chester RE: The Colorado thyroid
disease prevalence study. Arch Intern Med 2000, 160(4):526–534.
10. Hollowell JG, Staehling NW, Dana Flanders W, Hannon WH, Gunter EW,
Spencer CA, Braverman LE: Serum TSH, T4, and Thyroid Antibodies in the
United States Population (1998 to 1994): National Health and Nutrition
Examination Survey (NHANES III). J Clin Endocrinol Metab 2002,
87(2):489–499.
Palma et al. Diabetology & Metabolic Syndrome 2013, 5:58 Page 5 of 5
http://www.dmsjournal.com/content/5/1/5811. Ramos AJS, da Costa ADM, Benicio AVL, et al: Prevalência de Doença
tireoidiana em pacientes com diabetes tipo 1. Arq Bras Endocrinol Metab
2003, 47(2):177–182.
12. Souza OLR, Diehl LA, Carleto LD Jr, Garcia V, Carrilho AJF, Oliveira ML, et al:
Prevalência de auto-imunidade tireodiana em um grupo de pacientes
com diabetes mellitus tipo 1 em Londrina, PR. Arq Bras Endocrinol Metab
2005, 49(2):228–233.
13. Jaeger C, Petzoldt R, Hatziagelaki E, Bretzel RG: Comparative analysis of
organ-specific autoantibodies and celiac disease-associated antibodies in
type 1 diabetic patients, their first-degree relatives, and healthy control
subjects. Diabetes Care 2001, 24:27–32.
14. Hansen D, Bennedbaek FN, Hansen LK, Hoier-Madsen M, Jacobsen BB,
Hegedüs L: Thyroid function, morphology and autoimmunity in young
patients with insulin-dependent diabetes mellitus. Eur J Endocrinol 1999,
140:512–518.
15. Péres DS, Dos Santos MA, Zanetti ML, Ferronato AA: Dificuldades dos
pacientes diabéticos para o controle da doença:sentimentos e
comportamentos. Rev Latino Am Enfermagem 2007, 15(6):1105–1112.
16. Carvalho ALM, Leopoldino RWD, da Silva JEG, da Cunha CP: Adesão ao
tratamento medicamentoso em usuários cadastrados no Programa
Hiperdia no município de Teresina (PI). Cien Saude Colet 2012,
17(7):1885–1892.
17. Barbosa RGB, Lima NKC: Índices de adesão ao tratamento anti-
hipertensivo no Brasil e mundo. Rev Bras Hipertens 2006, 13(1):35–38.
18. Chubb SA, Davis WA, Inman Z, Davis TM: Prevalence and progression of
subclinical hypothyroidism in women with type 2 diabetes: the
Fremantle Diabetes Study. Clin Endocrinol (Oxf ) 2005, 62(4):480–486.
19. Chen HS, Wu TE, Jap TS, Lu RA, Wang ML, Chen RL, Lin HD: Subclinical
hypothyroidism is a risk factor for nephropathy and cardiovascular
diseases in Type 2 diabetic patients. Diabet Med 2007, 24(12):1336–1344.
20. Benseñor I: Screening for thyroid disorders in asymptomatic adults from
Brazilian populations. Sao Paulo Med J/Rev Paul Med 2002, 120(5):146–151.
21. Riley WJ, Maclaren NK, Lezotte DC, Spillar RP, Rosenbloom AL: Thyroid
autoimmunity in insulin dependent diabetes mellitus: the case for
routine screening. Pediatrics 1981, 9:350–354.
doi:10.1186/1758-5996-5-58
Cite this article as: Palma et al.: Prevalence of thyroid dysfunction in
patients with diabetes mellitus. Diabetology & Metabolic Syndrome
2013 5:58.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
